Capital Fund Management S.A. Raises Position in Biohaven Ltd. (NYSE:BHVN)

Capital Fund Management S.A. raised its holdings in Biohaven Ltd. (NYSE:BHVN - Free Report) by 130.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 38,488 shares of the company's stock after buying an additional 21,762 shares during the quarter. Capital Fund Management S.A.'s holdings in Biohaven were worth $1,438,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Spire Wealth Management acquired a new stake in Biohaven in the 4th quarter valued at $56,000. Amalgamated Bank raised its position in shares of Biohaven by 21.9% in the 4th quarter. Amalgamated Bank now owns 2,929 shares of the company's stock valued at $109,000 after buying an additional 527 shares in the last quarter. US Bancorp DE boosted its stake in Biohaven by 36.7% in the fourth quarter. US Bancorp DE now owns 2,971 shares of the company's stock valued at $111,000 after buying an additional 798 shares in the last quarter. KBC Group NV lifted its stake in shares of Biohaven by 50.1% in the 4th quarter. KBC Group NV now owns 3,377 shares of the company's stock valued at $126,000 after acquiring an additional 1,127 shares during the last quarter. Finally, Sanctuary Advisors LLC bought a new position in Biohaven in the 3rd quarter valued at approximately $246,000. Institutional investors and hedge funds own 88.78% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Deutsche Bank Aktiengesellschaft set a $60.00 target price on Biohaven and gave the company a "buy" rating in a research report on Thursday, March 20th. HC Wainwright restated a "buy" rating and set a $54.00 target price on shares of Biohaven in a research report on Tuesday, March 4th. Morgan Stanley lowered their price target on Biohaven from $69.00 to $63.00 and set an "overweight" rating on the stock in a report on Friday, March 7th. JPMorgan Chase & Co. reduced their price target on shares of Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a research report on Wednesday, March 5th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $61.00 price target on shares of Biohaven in a report on Tuesday, March 4th. Fourteen investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $62.77.

Insider Activity

In other Biohaven news, Director John W. Childs bought 32,700 shares of Biohaven stock in a transaction on Tuesday, March 4th. The shares were purchased at an average price of $30.47 per share, with a total value of $996,369.00. Following the acquisition, the director now owns 2,320,571 shares in the company, valued at $70,707,798.37. This trade represents a 1.43 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 16.00% of the stock is owned by insiders.

Biohaven Price Performance

NYSE:BHVN traded up $1.19 during mid-day trading on Monday, reaching $21.56. The stock had a trading volume of 307,181 shares, compared to its average volume of 1,098,369. Biohaven Ltd. has a fifty-two week low of $15.79 and a fifty-two week high of $55.70. The business's 50 day moving average is $28.43 and its 200 day moving average is $38.46. The stock has a market cap of $2.20 billion, a P/E ratio of -2.31 and a beta of 1.33.

Biohaven (NYSE:BHVN - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.29). Equities analysts expect that Biohaven Ltd. will post -8.9 EPS for the current year.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.